Search
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
Products: HYLASE® DESSAU 150 IU, POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION PARA ADMINISTRACIÓN OFTALMICAMecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalIn 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent
Synonyms: rhIGF-I/rhIGFBP-3, Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3Catfish
go.drugbank.com/drugs/DB14758ApprovedCatfish (unspecified) allergenic extract is used in allergenic testing.
Red pepper
go.drugbank.com/drugs/DB14759ApprovedRed pepper allergenic extract is used in allergenic testing.
Narlaprevir
go.drugbank.com/drugs/DB14760InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLanraplenib
go.drugbank.com/drugs/DB14770InvestigationalLanraplenib is under investigation in clinical trial NCT03285711 (Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)).
Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
go.drugbank.com/drugs/DB14771InvestigationalPolyacrylamide (crosslinked; 2 mole percent bisacrylamide) is under investigation in clinical trial NCT00629083 (Bulking Agents for the Treatment of Stress Urinary Incontinence in Females).
Synonyms: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)Camrelizumab
go.drugbank.com/drugs/DB14776InvestigationalCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Murepavadin
go.drugbank.com/drugs/DB14777InvestigationalMurepavadin is under investigation in clinical trial NCT02110459 (Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment).
Gancotamab
go.drugbank.com/drugs/DB14784InvestigationalGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs.